Aerocrine acquires FENO assets from FILT and enters into R&D collaboration

Aerocrine acquires FENO assets from FILT and enters into R&D
collaboration

SOLNA, Sweden - 18 March 2011 - Aerocrine AB today announced the
acquisition of key assets related to the measurement of FENO from German
company FILT Lungen & Thoraxdiagnostik GmbH.  FILT and Aerocrine will
collaborate to develop new applications for airway inflammation
monitoring and FILT will cease further commercialization of the NO
VARIO® product.

Over many years, Aerocrine has made very significant technological,
clinical and commercial investments to develop the market for its
inventions to measure airway inflammation in asthma and other
respiratory disorders.  Today, Aerocrine is the only company supplying
quality-assured products for FENO monitoring approved by major
regulatory authorities, including the FDA and SFDA, across the world. 
The company continues to invest in clinical trials and technology
development for the benefit of care providers and people living with
asthma.  

“The technology platform and intellectual property acquired from FILT
may prove valuable for our continued endeavors to further develop
innovative products to measure airway inflammation”, says Paul de
Potocki, CEO of Aerocrine.  “We look forward to working together with
FILT and its General Manager, Mr. Rüdiger Eichler, who brings
considerable technical expertise in the field.”
“It requires significant resources to develop the technology and the
international clinical documentation for products used in a major
therapeutic area such as asthma.  Aerocrine is the market leader and the
ideal partner for FILT related to airway inflammation monitoring,” says
Mr. Eichler.

Following the consummation of the agreements, Aerocrine will cause
appropriate papers to be filed in the Regional Court of Düsseldorf to
withdraw its pending claims of patent infringement against FILT.

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 80
Mats Carlson, VP Technical Operations & Development, telephone: +46 8
629 0783